Sign up online today & collaborate
or click here to find out more
SWATH® Acquisition-based next-generation proteomics technology promises to make “industrial” proteomics a reality
The University of Manchester opened the multi-million pound Stoller Biomarker Discovery Centre on June 14th 2016. It focuses on biomedical research including cancer, psoriasis and arthritis, utilizing mass spectrometry-based proteomics solutions from SCIEX. The opening of the Centre was marked with a special two-day scientific event, the Stoller Biomarker Discovery Centre Symposium, which took place on June 14th-15th 2016.
The Stoller Biomarker Discovery Centre, which was funded by a philanthropic gift from the Stoller Charitable Trust, the Medical Research Council and developed in partnership with SCIEX, will help to industrialize the process of identifying and utilizing protein biomarkers. With a large number of SCIEX LC-MS systems, the Centre is one of the biggest clinical proteomics facilities in the world, spearheading a series of biomarker development projects and international collaborations. It is helping to identify and develop markers of disease risk, diagnosis, response to therapy and prognosis on an industrial scale, aiding in the translation of biomarkers into the clinical lab.
SCIEX’s proteomics systems have been selected to deliver the comprehensive data that is so urgently needed in precision medicine. SCIEX’s patented SWATH® technology enables the quantification of thousands of proteins across large sample sets with a level of data completeness, quantitative accuracy, and reproducibility that was only previously achievable with ‘gold-standard’ targeted multiple reaction monitoring (MRM) methods. The SWATH next-generation proteomics technology will allow University scientists to collaborate with health companies and the National Health Service (NHS) to produce a greater number of tests and treatments, ultimately accelerating the process of eliminating many of the most serious illnesses faced today.
Professor Tony Whetton is the Director of the new Centre, and said: “The Centre is a major step forward in Precision Medicine. Essentially this is the future of healthcare – getting the right treatment to the right person at the right time and in the right dose. “Without biomarkers we won’t be able to identify which people will benefit from certain medicines, so this new centre underpins everything we’re doing in precision medicine in Manchester and beyond.”
The Stoller Biomarker Centre is located at CityLabs Manchester, in the midst of biotechnology companies, the Central Manchester University Hospitals, National Health Service (NHS) Foundation Trust and The University of Manchester. The new Centre houses a large suite of high-end SCIEX mass spectrometers for targeted next-generation proteomics, including TripleTOF® 6600 Systems with SWATH Acquisition, QTRAP® 6500+ Systems, and the SCIEX LipidyzerTM Platform. The University of Manchester has also invested in a number of liquid chromatography and automated sample preparation components for the Centre, from SCIEX and other Danaher life science companies, such as Beckman Coulter’s Biomek NXP Laboratory Automated Workstation.
“SCIEX’s mission of innovating integrated, reliable analytical tools to gain scientific understandings that lead to better health, enables our customers to advance precision medicine with scale and speed like never before,” states Jean-Paul Mangeolle, President of SCIEX. “And it takes more than providing great instruments to be part of a movement as important as Precision Medicine; it takes strong collaborations with customers, partnerships with industry leaders and teamwork with our colleagues at other Danaher Corporation life companies, to establish and deploy the most comprehensive proteomics solutions.”
The Centre was officially opened at the event attended by Professor Dame Nancy Rothwell, President and Vice-Chancellor of The University of Manchester, Sir Norman Stoller and trustees of the Stoller Charitable Trust, and Dan Daniel, Executive Vice President of Danaher, with a ceremony during the Stoller Biomarker Discovery Centre Symposium. At the conference, leading speakers from around the globe shared their insights into key topics surrounding precision medicine, including pioneers within the field such as Dr Leroy Hood, Dr Leigh Anderson, and Professor Jennifer Van Eyk.
Professor Rothwell said: “Manchester has become a major hub for precision medicine and proteomics and we are very grateful to the funders who have backed the cutting-edge work that is carried out by our scientists.”
“As a result of their generosity, The Stoller Biomarker Discovery Centre will start work on addressing some of the biggest issues in medicine in an environment where these discoveries can move quickly to improve people’s lives.”
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.
SCIEX social: Twitter: @SCIEXnews, LinkedIn and Facebook.
For Research Use Only. Not for use in diagnostic procedures.
AB Sciex is operating as SCIEX.
© 2016 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license. RUO-MKT-12-4288-A
Stacey Sicurella, Manager Global Public Relations and Brand, SCIEX
Kate Whelan, Notch Communications (on behalf of SCIEX)
+44(0)161 817 5008